Trial Profile
A study evaluating safety and efficacy of Lenvatinib in advanced radioiodine-refractory thyroid cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2018 New trial record
- 01 Mar 2018 Results published in the Anticancer Research